Drug-induced steatohepatitis (Q35184573)

7 August 2017

1 reference

title

Drug-induced steatohepatitis. (English)

1 reference

7 August 2017

0 references

R Todd Stravitz

1

1 reference

PubMed ID

12879993

7 August 2017

Arun J Sanyal

series ordinal

2

1 reference

7 August 2017

1 May 2003

1 reference

7 August 2017

Clinics in liver disease

1 reference

7 August 2017

7

1 reference

7 August 2017

435-451

1 reference

7 August 2017

2

1 reference

Drugs and the liver updated, 2002

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Drug-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Nonalcoholic steatohepatitis: definition and pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Mechanisms of hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone-induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Etiopathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone: reevaluation of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Increased hepatic density and phospholipidosis due to amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Abnormal abdominal computerized tomography with amiodarone therapy and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone hepatotoxicity. A clinicopathologic study of five patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Adverse effects of low dose amiodarone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Side effects and possible contraindications of amiodarone use.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone-induced liver toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone toxicity. II. Desethylamiodarone-induced phospholipidosis and ultrastructural changes during repeated administration in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Amiodarone hepatotoxicity simulating alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Perhexiline maleate toxicity on human liver cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Tamoxifen-induced fatty liver in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Tamoxifen-associated steatohepatitis--report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Tamoxifen-induced steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Tamoxifen-induced steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Cirrhosis with steatohepatitis after adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

"Nonalcoholic steatohepatitis" induced by massive doses of synthetic estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Diethylstilbestrol-induced jaundice in the Chinese and Armenian hamster.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Hepatic reactions to nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Alcoholic-like liver lesions induced by nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Hepatic injury possibly induced by verapamil.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Possible hepatitis from verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Methotrexate and histologic hepatic abnormalities: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900027-8

7 January 2021

10.1016/S1089-3261(03)00027-8

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12879993